Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Trial Evaluates IMGN901 for Small-Cell Lung Cancer

By R&D Editors | November 30, 2010

ImmunoGen, Inc. announced the initiation of a randomized Phase 1/2 clinical trial to evaluate its proprietary product candidate, IMGN901 (lorvotuzumab mertansine), for first-line treatment of small-cell lung cancer (SCLC) in patients with extensive disease.

“We believe IMGN901 has the potential to be an important treatment for SCLC, particularly as part of a combination regimen,” commented James O’Leary, MD, vice president and chief medical officer. “IMGN901 has been found to be well tolerated and to demonstrate evidence of activity when used as a single agent to treat this highly aggressive cancer. The tolerability profile of IMGN901 supports evaluating it in combination with other active agents and, in preclinical testing, it has shown highly compelling activity used together with these same therapies.”

This multi-national trial will evaluate IMGN901 used together with carboplatin plus etoposide (C/E)—standard care for first-line treatment of SCLC—versus C/E alone. In the dose escalation Phase I portion of the trial, increasing doses of IMGN901 will be administered with C/E to establish the maximum tolerated dose of the study compound with C/E. In the Phase II portion, patients will be randomized to receive C/E plus IMGN901 (60 patients) or C/E alone (30 patients). 

IMGN901 will be administered weekly for two weeks in a three-week cycle, and C/E will be dosed on the standard three-week schedule. Patients can receive up to six cycles of C/E, consistent with established usage, but those randomized to also receive IMGN901 will be allowed to remain on the study drug alone as long as they continue to benefit from it.

The primary endpoint of this trial is progression-free survival (PFS). Secondary endpoints include PFS at 6 months, overall survival at 12 months, time to progression, overall survival and overall response rate.

Date: November 30, 2010
Source: ImmunoGen, Inc. 

Related Articles Read More >

2025 R&D layoffs tracker tops 92,000
Health-related innovation in Morocco highlighted by resident inventor patenting activity
ARPA-H funds $29M Ginkgo-led project to reshore pharma supply chains using wheat germ tech
DNA microscope offers new 3D view of organisms from the inside out
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE